The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
It’s quite likely that one of these popular anti-obesity medications will be selected for negotiation in the next round of Medicare’s relatively new drug price negotiation program.
The Trump Administration could go in one of three directions with the Medicare negotiations program: stay the course, water it down or repeal it all together. There are potential tradeoffs with each, but the first would be most popular.
The report describes the U.S. pharmaceutical supply chain, following prescription drugs as they move from manufacturers, to wholesale distributors, to pharmacies, and ultimately to patients. The report describes both the physical distribution of drugs through the chain, as well as the flow of money and the financial relationships among the key players. It was prepared for the Foundation by Dan Mendelson and The Health Strategies Consultancy. Report (.pdf)
This report describes and reviews various options to address prescription drug spending growth, including a description of each cost-containment strategy, its use by private or public payers, and a discussion of known evidence about its effectiveness or cost-saving potential. It was prepared for the Kaiser Family Foundation by Jack Hoadley, Ph.D., of the Health Policy Institute at Georgetown University. Report (.pdf)
Additional Help with Prescription Drug Costs For Low-Income People on Medicare (For 2007 Benefits and Cost-Sharing) As of 2007, Medicare helps pay for outpatient prescription drugs. Medicare provides additional help with drug costs to beneficiaries who qualify based on low incomes and limited resources. The information below describes the different levels of assistance available to people who meet the eligibility requirements. People on Medicare Who Also Have Full Medicaid Benefits (Dual Eligibles) pay: No premium…
This paper, by John F. Hoadley, Ph.D., of the Health Policy Institute at Georgetown University, examines how formulary designs and other cost-management tools may affect Medicare beneficiaries’ access to medications through their Medicare Part D prescription drug plans. It is one in a series commissioned by the Kaiser Family Foundation that analyzes issues surrounding the implementation of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and the proposed regulations. Issue Brief (.pdf)
This survey documents the increasing costs of retiree benefits for both large private-sector employers and their retirees. It also provides an early look at the response of large employers to the Medicare prescription drug law and the subsidies it provides for maintaining retiree drug coverage. Download Full Report (.pdf) Chartpack (.pdf)
Employer Health Benefits 2003 Annual Survey View All Charts for This Section Monthly Premium Costs of Single and Family Coverage In 2003, average monthly premiums for single and family coverage (including worker and employer share of premium) are $282 and $756 respectively (Exhibit 1.12). The cost of family coverage is now nearly $9,100 per year. Average monthly premiums for PPO plans, which cover most Americans, are $292 for single coverage and $776 for family coverage.…
Prescription Drug Costs Download a printable .pdf of Health Care and the 2004 Elections: Prescription Drug Costs. IssueBackgroundOptions for for making prescription drugs more affordableAssessing Candidate PositionsIssue Health care costs in general have grown faster than the economy. Although still only a modest part of total health care spending in the United States (11% in 2002), the growth in pharmaceutical spending has outpaced other categories of health care services over the last few years. What,…
Two new KFF analyses examine the potential impact of Medicare coverage of new prescription drugs for obesity and Alzheimer’s disease on program spending and beneficiary out-of-pocket costs, as well as the role that the Inflation Reduction Act could play in mitigating these effects. Manufacturers of both types of drugs are lobbying for broad Medicare coverage of them, though they face different challenges. The availability of effective weight-loss drugs, including Novo Nordisk’s Ozempic and Wegovy (semaglutide)…
© 2026 KFF